Introduction {#sec1_1}
============

Mutations in *KIT* oncogene are characteristic for gastrointestinal stromal tumors (GISTs) and for mucous and acral melanoma subtypes. Spectrum of *KIT* mutations in melanomas is slightly different from the one observed in GISTs, with exon 13 mutation p.K642E accounting for significant share of *KIT*-driven tumors \[[@B1]\]. Some amino acid changes in *KIT* protein render tumors sensitive to imatinib, while others are associated with drug resistance \[[@B2]\]. Given the rarity of both GISTs and mucosal and acral melanomas, the cataloguing of predictive role of various *KIT* mutations represents a challenge. Here we describe a melanoma patient with a rare *KIT* mutation, who failed to respond to imatinib.

Case Report {#sec1_2}
===========

In February 2015, a 67-year-old woman was diagnosed with T4bN0M0 melanoma of the left heel. Multiple metastatic lesions affecting inguinal lymph nodes and lungs were detected 10 months after the surgery. First-line therapy by dacarbazine (2 cycles) was administered in April 2016 and was accompanied by the disease progression. Second-line therapy (paclitaxel and carboplatin, 2 cycles), being started in June 2016, also failed to stop tumor growth. At the beginning of chemotherapy the patient was also diagnosed with a brain lesion; the metastatic nature of this lesion was initially under the question, therefore this lump was left for observation. During the course of chemotherapy this brain lesion gradually increased in size, therefore the gamma-knife treatment was applied in August 2016. Very few treatment options were left for the patient after the failure of the second-line chemotherapy. The immunotherapy could not be considered due to several limitations: ipilimumab was the only immune checkpoint inhibitor registered in Russia by that time, however it could not be easily administered due to financial constraints; also, there was no available clinical trials utilizing immune-based approaches. Meanwhile, the analysis of tumor tissue, which was removed at primary surgery, revealed a somatic *KIT* mutation р.T632I. This substitution has been repeatedly described in the literature, however no data on its sensitivity to imatinib is available \[[@B3], [@B4]\]. Similarly, there is no consistent data on the predictive value of other rare *KIT* mutations, which are located in the proximity to codon 632 \[[@B2], [@B5]\]. The closest known predictive mutation is p.K642E, which is located in the same part of the KIT protein (ATP-binding domain, C-helix, residues 631--647) and is clearly associated with tumor responsiveness to imatinib \[[@B6], [@B7], [@B8]\]. Based on this evidence, the patient was administered imatinib 400 mg twice a day. This treatment was accompanied by grade II anemia and grade II periorbital edema. The condition of the patient worsened during the imatinib therapy, with growing fatigue and ECOG status changing from 0 to 2--3. New metastatic lump was detected in the soft tissue of the left limb and the enlargement of inguinal lymph nodes was observed. Imaging analysis was performed at the 7th week of the therapy and revealed enlargement of tumor lesions (Fig. [1](#F1){ref-type="fig"}). Based on these data, targeted treatment was discontinued. The patient was offered best supportive care and died in December, 2016 due to further disease progression in soft tissues and lungs.

Discussion {#sec1_3}
==========

The efficacy of imatinib for the treatment of melanomas carrying *KIT* gene mutation has been repeatedly demonstrated in several clinical studies. However, not all *KIT* mutations render imatinib sensitivity, with melanoma response rates being generally lower than in *KIT*-mutated GISTs; they usually approach to 20--25% when all *KIT* genetic lesions are considered, and reach 35--50% in melanomas with exon 11 and 13 *KIT* mutations \[[@B7], [@B9], [@B10]\]. Notably, the relationships between particular *KIT* mutations and tumor responsiveness to imatinib are not always straightforward: even tumors with identical mutations may vary in their sensitivity to the treatment \[[@B7]\]. In particular, *KIT*-mutated tumors may demonstrate distinct addiction to *KIT* signaling, depending, for example, on the ratio between the affected and the wild-type alleles \[[@B7]\]. Presence of other driver mutations, e.g., in *NRAS* oncogene, may also impair the imatinib efficacy \[[@B10]\]. In addition, down-regulation of apoptotic pathways, intratumoral heterogeneity and plasticity of transformed cells are likely to contribute to melanoma therapy resistance \[[@B11], [@B12], [@B13]\].

We assume that treatment failure in the described case does not yet preclude administration of imatinib to other patients with *KIT* р.T632I or closely located mutations. However, the treatment responses of tumors with rare *KIT* mutations deserve systematic registration in order to accumulate a critical mass of evidence and guide a drug administration with a better level of precision. Current data on relevant genotype-response correlations for *KIT* mutations are summarized in online supplementary Tables [1--9](#S1){ref-type="supplementary-material"} (for all online suppl. material, see [www.karger.com/doi/10.1159/000495782](http://www.karger.com/doi/10.1159/000495782)).
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